Analyst Gaurav Maini from LifeSci Capital maintained a Buy rating on Tectonic Therapeutic and keeping the price target at $88.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Gaurav Maini has given his Buy rating due to a combination of factors related to both clinical strategy and financial positioning. He views Tectonic’s TX45 program as differentiated from AstraZeneca’s discontinued relaxin Fc-fusion, emphasizing that APEX is selectively enrolling patients with combined pre- and post-capillary PH and elevated PVR, where a reduction in PVR is clinically more plausible and directly aligned with the primary endpoint.
He also highlights TX45’s pharmacokinetic profile as a potential competitive advantage that could translate into stronger and more durable activity, with convenient subcutaneous dosing every two to four weeks. In addition, he notes that Tectonic has roughly three years of cash runway based on its current burn and share count, which he believes provides sufficient time to reach key Phase 2 readouts in 2026 and potentially unlock value despite elevated short interest in the stock.